Efficacy and safety of simeprevir with pegylated interferon alfa and low dose of ribavirin for patients with chronic hepatitis C genotype 1 and low hemoglobin level
Not Applicable
- Conditions
- Patients with chronic hepatitis C virus infection
- Registration Number
- JPRN-UMIN000018476
- Lead Sponsor
- Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1) Co-infection with hepatitis B virus 2) Co-infection with anti-human immunodeficiency virus 3) Other forms of liver disease (alcohol liver disease, autoimmune hepatitis etc.) 4) Decompensated cirrhosis, Liver failure 5) Severe multisystem disease, Severe immunodeficiency 6) Contraindication to pegylated interferon 7) Contraindication to ribabirin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method